


Sulphonamides

→ The first effective chemotherapeutic agents to be employed systemically.



Basic structure

→ Nature: → White powder, insoluble in H₂O & acidic in nature.

When treated with bases, it forms a salt which is insoluble in water. Whereas sodium salts are very soluble.

For Eg:- Sodium sulfacetamide → soluble in H₂O
pH → Basic (very high) → damages the tissues
∴ used topically.

History: → PRONTOSIL → Sulfonamide group.

→ 1933, Foerster reported that prontosil given to 10-month old infant with staphylococcal septicemia and achieving a dramatic cure.

→ Also used in puerperal sepsis, meningococcal infections etc

→ Development of carbonic anhydrase inhibitor-type diuretics & sulfonylurea hypoglycemic agents were followed by development of sulfonamide antibiotics.

→ For discovery of Prontosil value, Domagk was awarded Nobel prize.

Chemistry: → Derivative of Para-Aminobenzenesulfonamide [Sulfanilamide]

The important feature is the sulfur linked directly to benzene ring.

- Para- NH_2 group is essential and can be replaced only by moieties that can be converted *in vivo* to a free amino group.
- Substitutions made in N_1 ($-\text{NH}_2$) group have variable effects on Antibacterial activity of molecule.
- N_1 substitution by Heterocyclic aromatic nuclei yields highly potent compounds.

Classification :-

Based on Rate of absorption and excretion.

I. Rapidly absorbed and rapidly excreted

Sulfisoxazole $t_{1/2}$ 5-6 hrs

Sulfamethoxazole 11 hrs

Sulfadiazine 10 hrs.

II. Poorly absorbed & remain active in bowel lumen

Sulfasalazine

III. Topically used : Sulfacetamide Silver Sulfadiazine Mafenide

IV. Long acting : Sulfadoxine 100-230 hrs.

Based on Uses :-

I. Used in Treatment of Systemic infections.

Short acting → Sulfadiazine, Sulfamethizole
~~Sulfacetamide~~
 Sulfa furazone, Sulfadimidine

Intermediate acting : \rightarrow Sulfamethoxazole

Long acting : \rightarrow Sulfamethoxy pyridazine
Sulformethoxine, sulfadoxine,
Sulfadimethoxine

ii. Used in the treatment of ulcerative colitis
Sulfasalazine.

iii. Used topically : Silver sulfadiazine, Sulacetamide,
Mefenide.

Antibacterial spectrum :

Active against both gram +ve & gram -ve bacteria.

Bacteriostatic in Nature.

<u>Susceptible strains</u>	: \rightarrow	Streptococcus pyogenes
Staphylococci	"	pneumoniae
Haemophilus	"	influenzae
Neisseria	"	dubreyi
Meningococci		Nocardia
		Actinomyces
		Calymmatobacterium granulomatis
		Chlamydia trachomatis


MIC for chlamydia $\frac{0.1}{4-64}$ $\mu\text{g}/\text{ml}$

E.coli $4-64 \mu\text{g}/\text{ml}$

Peak plasma concn. $\text{in vivo} \Rightarrow \sim 100-200 \mu\text{g}/\text{ml}$.

Resistant strains : \rightarrow Neisseria meningitidis
Shigella & E.coli from UTI.

Mechanism of Action : → Competitive inhibitors of dihydropteroate synthase



Folic Acid

Folic acid synthesis : →

PABA + Pteridine

↓ dihydropteroate synthase (X) sulfonamide
Dihydropteroic acid

↓ Glutamate
Dihydro folic acid

NADPH
NADP⁺ ↓ dihydro folic acid reductase (X) Trimethoprim
Tetra hydro folic acid

- Dihydropteroate synthase is a bacterial enzyme responsible for the incorporation of PABA into dihydropteroic acid, the immediate precursor of folic acid.
- Sulphonamides are structural analogs of PABA & prevent normal bacterial use of PABA for the synthesis of folic acid.
- Synthesis of folate is a metabolic pathway found only in bacteria but not in humans. Humans can't synthesize folic acid but are absorbed from the diet via transport mechanism across the cell.
- Cells utilize folate in the form of Tetrahydrofolate as a cofactor in Thymidylate synthesis.
- Bacteria which use preformed folic acid can't be killed / stoppage of growth by sulphonamides.
- Synergistic effects : combination ~~of~~ with trimethopis

Development of Resistance :-

- Resistance once developed, ~~is~~ usually is persistent and irreversible.
 - Acquired resistance doesn't involve cross resistance
- Resistance is the consequence of altered enzymatic constitution of Bacterial cell. The alteration may be characterised by .
- lower affinity of dihydropteroate synthase for sulphonamides

- 2 Decreased bacterial permeability or active efflux of the drug.
- 3 An alternative metabolic pathway for synthesis of essential metabolite
- 4 ↑ production of an essential metabolite or drug antagonist.
- 5 Plasmid-mediated resistance: is due to plasmid encoded drug-resistant dihydropteroate synthase.

D. kinetics :

Absorption:

- Except sulfasalazine, All other drugs are absorbed rapidly from G.I.T. (small intestine).
70-100% absorbed and can be found in urine within 30 minutes.
- Small intestine is the major site of absorption. However, some drugs are absorbed from stomach.
- Absorption from other sites like Vagina, respiratory tract or abraded skin is variable & unreliable but sufficient amount may enter the body to cause toxic reactions.
peak plasma levels within 2-6 hrs.

Distribution :-

- Distributed throughout all tissues of the body.
- Distributed in pleural, peritoneal, synovial, ocular, etc.
- Adequate doses of Sulfadiazine & sulfisoxazole attain conc' in CSF upto 50-80% of that of plasma levels.
- Varying degree of plasma proteins especially to albumin. At least 50%. Bound to plasma proteins. Drugs with high pKa exhibit low degree of protein binding & vice versa.
- Crosses placental barrier & reach fetal circulation. The conc' attained in the fetal tissues ~~can~~ cause both antibacterial and toxic effects.

Metabolism :-

- Metabolism in liver to metabolic derivative N₄-acetylated sulfonamide. It is not active but toxic potential is retained.
- Acetylation occurs differently with different drugs.
- Rapid acetylators : 62-90% metabolised
Slow acetylators : 40-53% " "
- Acetylated form → is devoid of antibacterial activity
note → Possess toxic potencies of parent drug
 - poorly soluble in urine → causing crystalluria & renal complications.
- t_{1/2} depends on renal function.

Protein Binding:

- Bound sulfonamide has much less bactericidal activity and cannot normally pass into tissue fluids or BBB.
- Since the bound form is not available for renal excretion, protein binding helps to prolong their action.
- The highly protein bound sulfonamides are not so effective in the treatment of acute infections bcoz of low plasma levels of free sulfonamide.

Excretion:

- Eliminated from body in unchanged & metabolized form through kidneys.
- also eliminated through bile, milk & other secretions
- May ppt. in urine → crystalluria.

Adverse effects:

- Drug fever, Urticaria
- Crystalluria → Can be Treated with ↑ Water intake to make daily Urine volume 1200 ml / day in adults. (or)

Alkalinize Urine → Acidic drugs in alkaline pH will be more ionised. No reabsorption and excretion done quickly.

- Acute Hemolytic anemia → seen in people with glucose -6- phosphate dehydrogenase deficiency.
 - ↓
(protects RBC)
- Agranulocytosis → ~ 0.1% of patients
- Aplastic anemia, Thrombocytopenia → due to depression of Bone marrow.
- Hypersensitivity Reactions → Variable. (long acting drugs)
 - Enzyme multiforme of Stevens-Johnson type
 - Drug fever, Eosinophilia, Serum sickness
 - ↓
May develop within 2 weeks of therapy.
 - Fever, Joint pain, Urticaria, Bronchospasm, Leucopenia
- Anorexia, Nausea, Vomiting in 1-2% of patients
- In Newborn, admin. of sulfonamides may lead to displacement of Bilirubin from plasma albumen. The free Bilirubin deposited in Basal ganglia & substantia nigra of brain → encephalopathy called Kernicterus.
- CNS toxicity → Confusion, depression, Ataxia, fatigue, Anti psychotic episodes, peripheral neuritis etc.
- Not to be given in pregnancy → crosses placental barrier & secreted in milk.

Drug Interactions :-

- 1 → oral anticoagulants (Warfarin) → Albumin displacement
↓
Same carrier protein
↓
excessive bleeding
- 2 → sulfonylureas → potentiate effects of hypoglycemic activity
- 3 → Hydantoin → synergistic activity due to inhibition of metabolism . ∴ action ↑

T. Uges :-

- in UTI
- Nocardiosis
- Toxoplasmosis
- prophylactically used in rheumatic fever;
Streptococcal infections in people sensitive to penicillin.